Integrum (INTEG) Investor Update summary

Business update and strategic focus

• Emphasis on building an empowered, performance-driven culture and prioritizing profitable sales growth.

• Focus on sales force productivity, leadership, and disciplined product launches to drive shareholder value.

• Strategic efforts include targeting the right geographies and customer segments, especially prosthetists and orthopedic surgeons.

• Ongoing initiatives to address insurance pushback from private payers and improve patient identification and referral processes.

• Board is engaged in a strategic process to enhance scalability, including potential partnerships.

Financial performance and operational goals

• Q1 net sales were SEK 18.5 million, a 9.5% decrease year-on-year, with negative EBIT margins.

• Operational focus on maximizing return on invested capital and ensuring investments are justified by expected returns.

• Recent capital raise is earmarked for investment in sales and marketing to support growth.

Sales and market development

• Direct sales team targets prosthetists, while independent reps focus on orthopedic surgeons and hospitals.

• Market research with prosthetists is informing new sales strategies and organizational adjustments.

• Key challenge is identifying and referring suitable patients, leveraging partnerships with prosthetists and hospitals.

• No direct answer provided on current US sales ramp-up.